Caribou Biosciences to Participate in Upcoming Investor Conferences
2024年2月16日 - 6:05AM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading
clinical-stage CRISPR genome-editing biopharmaceutical company,
today announced the company’s participation in the following
investor conferences:
- Citi's 2024 Virtual Oncology
Leadership SummitFebruary 21, 2024, fireside chat at 12:00 pm
EST
- Leerink Global Biopharma
ConferenceMarch 12, 2024, fireside chat at 1:40 pm EDT
- Barclays Global Healthcare
ConferenceMarch 13, 2024
- H.C. Wainwright 2nd Annual Cell
Therapy Virtual ConferenceMarch 26, 2024, fireside chat at 11:30 am
EDT
For more information and links to available webcasts, visit
the Events page on Caribou’s website. Webcasts will be
available on the Caribou website for 30 days after the events.
About Caribou’s novel next-generation CRISPR
platformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its Cas12a chRDNA technology,
enables superior precision to develop cell therapies that are
armored to potentially improve antitumor activity. Caribou is
advancing a pipeline of off-the-shelf cell therapies from its CAR-T
and CAR-NK platforms as readily available treatments for patients
with hematologic malignancies and solid tumors. Follow us
@CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc.
contacts:Investors:Amy Figueroa,
CFAinvestor.relations@cariboubio.com
Media:Peggy Vorwald,
PhDmedia@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
過去 株価チャート
から 4 2024 まで 5 2024
Caribou Biosciences (NASDAQ:CRBU)
過去 株価チャート
から 5 2023 まで 5 2024